.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,283,193

« Back to Dashboard

Claims for Patent: 9,283,193

Title:Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.
Inventor(s): Oberg; Keith A. (Valencia, CA), Sulner; Joseph (Paramus, NJ), Grant; Marshall L. (Newtown, CT)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:14/249,621
Patent Claims: 1. A microparticle comprising a fumaryl diketopiperazine (FDKP) core microparticle and an insulin coating, wherein the insulin coating is about 9% to about 12% of the total weight of the microparticle.

2. The microparticle of claim 1, wherein the insulin coating is a continuous or non-continuous monolayer.

3. The microparticle of claim 1, wherein at least about 9% insulin, based upon the total weight of the microparticle, is bound to the core microparticle.

4. The microparticle of claim 3, wherein at least 75% of the insulin coating is bound to the core microparticle.

5. The microparticle of claim 4, wherein the insulin coating is bound so that at least 75% of the insulin coating will remain on the core microparticle surface when the microparticle is dispersed in water.

6. The microparticle of claim 3, wherein at least about 9% insulin, based upon the total weight of the microparticle, is electrostatically bound to the core microparticle.

7. The microparticle of claim 1, wherein the insulin coating is about 11.4% of the total weight of microparticle.

8. The microparticle of claim 1, wherein the core microparticle further comprises polysorbate 80.

9. The microparticle of claim 7, wherein the core microparticle further comprises polysorbate 80.

10. The microparticle of claim 9, wherein the polysorbate 80 is present in an amount of at least 0.007 mg/mg of microparticle.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc